A host of studies unveiled this summer comparing the drug-eluting stents (DES) of Boston Scientific (Natick, Massachusetts) and the Cordis (Miami Lakes, Florida) unit of Johnson & Johnson (J&J; New Brunswick, New Jersey) have added to the confusion over which device-drug combination is better suited for the treatment of coronary artery disease and the prevention of in-stent restenosis.